spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product LinesConnecting Medical Sales Reps with MedTech/BioPharma Recruiters and Independent Reps with and New Product Lines

Searching News Database:  Satiety 

 HSMN NewsFeed - 6 Apr 2026
Neurocrine to Acquire Soleno Therapeutics, Expanding Its Endocrinology and Rare Disease Portfolio
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 19 Jan 2022
Titan SGS(R) from Standard Bariatrics, Inc. Passes 1,000 Clinical Case Uses
Devices Surgery
 HSMN NewsFeed - 13 Dec 2021
Standard Bariatrics, Inc. Reaches Sales Milestone with Titan SGS(TM)
Devices Surgery
 HSMN NewsFeed - 4 May 2021
Standard Bariatrics(R) Titan SGS Stapling Technology for Sleeve Gastrectomy Receives FDA Clearance
Devices Surgery FDA
 HSMN NewsFeed - 9 Jun 2020
Saluda Medical Appoints Jim Schuermann as President and Robert Gaffney as Chief Operating Officer
Devices Neurology Personnel
 HSMN NewsFeed - 25 Mar 2020
Kallyope Inc. Announces $112M Series C Financing to Support First Clinical Trials and Advance Portfolio of Programs Targeting the Gut-Brain Axis
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 4 Jan 2018
Neurogastrx, Inc. Raises $45M Series A To Bring Lead GI Candidate Through Proof Of Concept
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 30 Jun 2016
OPKO Health to Acquire Transition Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 9 Jan 2014
Covidien, Lightstone Ventures, New Enterprise Associates Announce Series A Investment in FIRE1
Devices Venture Capital Personnel
 HSMN NewsFeed - 9 Oct 2013
USGI Medical Receives FDA Approval to Launch Head-to-Head Pivotal Study to Determine Safety, Effectiveness of Incisionless, Endoscopic Weight Loss Procedure
Devices Surgery FDA
 HSMN NewsFeed - 7 Jun 2013
Eisai Announces Availability of BELVIQ(R) (lorcaserin HCl) CIV Tablets for Chronic Weight Management in Adults who are Overweight with a Comorbidity or Obese
Biopharmaceuticals
 HSMN NewsFeed - 14 Feb 2013
Elcelyx Therapeutics Completes $20 Million Series C Financing to Advance NewMet and Lovidia
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 23 Dec 2011
VIVUS Announces Date of FDA Advisory Committee Review of Qnexa for the Treatment of Obesity
Biopharmaceuticals
 HSMN NewsFeed - 18 Oct 2011
Tranzyme Pharma Names Former Gilead Executive Franck Rousseau, M.D. Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Aug 2011
Obese Patients Treated With QNEXA Demonstrated Significant Improvement in Quality of Life
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 21 Jan 2011
VIVUS Provides Regulatory Update on QNEXA NDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2010
VIVUS Files European Marketing Authorization Application for QNEXA(R) in the Treatment of Obesity
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2010
Satiety’s TOGA(R) System Named a Top Medical Innovation by Cleveland Clinic Experts
Devices Gastroenterology
 HSMN NewsFeed - 1 Jul 2010
Eisai to Market Arena Pharmaceuticals' Lorcaserin for Obesity and Weight Management in U.S. Following FDA Approval
Biopharmaceuticals
 HSMN NewsFeed - 1 Jul 2010
Eisai Inc. Enters Marketing and Supply Agreement with Arena Pharmaceuticals for Lorcaserin
Biopharmaceuticals
 HSMN NewsFeed - 22 Apr 2010
Gelesis Unveils Novel Non-Invasive Capsulated Device for Obesity and Presents Clinical Data; Appoints Former Pfizer R&D President to Board
Devices Personnel
 HSMN NewsFeed - 26 Feb 2010
Arena Pharmaceuticals Receives PDUFA Date for Lorcaserin NDA
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Jan 2010
The Foundry Announces Completion of Series A Financing for Twelfth Company
Devices Venture Capital
 HSMN NewsFeed - 29 Dec 2009
VIVUS Submits Qnexa(R) New Drug Application to the FDA for the Treatment of Obesity
Biopharmaceuticals FDA
 HSMN NewsFeed - 13 Nov 2009
Phase II/III Clinical Study Compares Safety and Efficacy of Two Doses of ZENPEP(TM) (Pancrelipase) Delayed-Release Capsules for Fat Absorption in Adult Chronic Pancreatitis Patients With Exocrine Pancreatic Insufficiency
Biopharmaceuticals
 HSMN NewsFeed - 8 Sep 2009
Salix Receives FDA Marketing Approval for METOZOLV ODT (Orally Disintegrating Tablets) for Relief of Diabetic Gastroparesis and Symptomatic Documented GERD
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 28 Aug 2009
Eurand Granted FDA Approval for ZENPEP(TM)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 May 2009
Results From Phase 3 EQUATE Trial of VIVUS' Qnexa Highlighted at European Congress on Obesity
Biopharmaceuticals
 HSMN NewsFeed - 28 Jan 2009
The Foundry Announces New Partners and Completion of Series A Financing for Eleventh Company
Devices Venture Capital Personnel
 HSMN NewsFeed - 13 Oct 2008
Miramar Labs Names Zoromski As CEO
Devices Dermatology Personnel
 HSMN NewsFeed - 15 Sep 2008
7 Health Ventures Invests in Tulip Medical
Devices Venture Capital
 HSMN NewsFeed - 12 Nov 2007
Allergan, Inc. and Covidien Ltd. Enter into Co-Promotion Agreement for LAP-BAND(R) Adjustable Gastric Banding System
Devices
 HSMN NewsFeed - 9 Oct 2007
ForSight Labs Announces Acquisition of ForSight Newco II by QLT, Inc.
Biopharmaceuticals Ophthalmology Acquisitions
 HSMN NewsFeed - 24 Jul 2007
OREXIGEN(TM) Therapeutics Reports Top-line 24 Week Results for Phase IIb Trial of EMPATIC(TM) to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 17 Jul 2007
Satiety, Inc. Completes $30 Million Series D Financing
Devices Gastroenterology Venture Capital
 HSMN NewsFeed - 21 Jun 2007
VIVUS Completes End of Phase 2 Meeting with the FDA for Qnexa, a Treatment for Obesity
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2007
EndoGastric Solutions, Inc. Completes Five Fully Transoral Redo-Obesity Procedures: Without Skin Incision - In As Little As 20 Minutes
Devices
 HSMN NewsFeed - 22 Nov 2006
OREXIGEN(TM) Therapeutics Completes $30 Million Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 Oct 2006
OREXIGEN(TM) Therapeutics Reports Positive Phase II Results for Excalia(TM) Combination-Therapy to Treat Obesity
Biopharmaceuticals
 HSMN NewsFeed - 4 Oct 2006
OREXIGEN(TM) Therapeutics Expands Senior Management Team as Lead Products Advance Through Late-Stage Clinical Trials
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Sep 2006
Arena Pharmaceuticals Initiates Lorcaserin Phase 3 Obesity Clinical Trial
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
OREXIGEN(TM) Therapeutics Appoints Graham Cooper as Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 May 2006
VIVUS Announces Positive Phase 2 Clinical Trial Results With Qnexa, a Novel Therapy to Treat Obesity
Biopharmaceuticals
Return to NewsFeed  

 Additional items found! 15

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 15 additional stories matching:
Satiety
(Password required)
FindReps - screen and connect with rep candidates anonymously, in real time.

FindReps: Screen and connect with Medical Sales Rep candidates (Direct Reps and Independents) – anonymously, in real time.


RepJobs - Job Opportunities for Direct Sales Reps and New Product Lines for Independents!

RepJobs: Job Opportunities for Direct Sales Reps and New Product Lines for Independents!